Showing 15 posts of 28 posts found.


Court sides with Amgen in Sandoz’ challenge over patent on Enbrel

August 12, 2019
Sales and Marketing Enbrel, IP, Novartis Amgen, court, patent, pharma

A US court has sided with Amgen in a legal battle over the patent on blockbuster rheumatoid arthritis drug Enbrel. …


FDA approves first therapy for paediatric psoriasis treatment

November 7, 2016
Sales and Marketing Amgen, Enbrel, paediatric, psoriasis

Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. …


FDA approves Novartis Enbrel biosimilar

August 31, 2016
Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar, erzeli

Novartis, through its Sandoz division, has announced that the FDA has approved Erelzi (etanercept-szzs), a biosimilar of Amgen’s blockbuster drug …

FDA recommends Novartis’s biosimilar for Enbrel in unanimous vote

July 14, 2016
Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar

Sandoz, a division of Novartis, has announced that a US Food and Drug Administration (FDA) advisory committee has recommended their …


New data shows Sandoz’s Enbrel biosimilar has equivalent efficacy profile

July 7, 2016
Research and Development, Sales and Marketing Amgen, EMA, Enbrel, FDA, Novartis, Sandoz, biosimilars

Sandoz has announced new data confirming the equivalent safety and efficacy profile of their biosimilar version of Enbrel (etanercept) in …

Sandoz biosimilars as safe and efficacious as originators, says early trials data

June 9, 2016
Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab

Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …


New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016

June 8, 2016
Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5

Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …


Amgen raises 2016 outlook after Q1 earnings boost

April 29, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Enbrel, etanercept, financial results, financials, sales rise

Amgen (NASDAQ: AMGN) has upgraded their 2016 outlook after posting an increase of 10% in revenues for the first quarter …


FDA approves Lilly’s plaque psoriasis drug Taltz

March 23, 2016
Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …


Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials

March 7, 2016
Research and Development, Sales and Marketing Eli Lilly, Enbrel, ixekizumab, psoriasis

Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one …


First Enbrel biosimilar launches in UK

February 16, 2016
Manufacturing and Production, Research and Development Enbrel, Samsung Bioepis, eternacept, rheumatoid arthritis

Following its approval by the European Commission in January, Benepali has become the first biosimilar of Pfizer/Amgen’s Enbrel (etanercept) to …


Biosimilars: Can the US catch up in 2016?

February 12, 2016
Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars

What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …

Samsung beats pharma to develop first EU-approved Enbrel biosimilar

January 18, 2016
Manufacturing and Production Benepali, CHMP, EMA, Enbrel, Samsung, Samsung Bioepis, etanercept, positive opinion

Samsung Bioepis – the collaboration between Samsung Biologics and Biogen Idec, has become the first company to have a biosimilar …

Baxalta logo

Baxalta’s Enbrel biosimilar measures up in late-stage study

January 13, 2016
Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis

Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …

New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs

December 16, 2015
Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin

NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …

Latest content